Alliance for Pharmacy Compounding

04/20/2026

Map shows status of restrictive compounding legislation in states as of April 15.

California

AB 1990 cleared the Business & Professions Committee on April 14 with a “do pass as amended” vote, advancing it to the Committee on Privacy and Consumer Protection, where it has a hearing scheduled for April 21. APC Board Vice President Peter Koshland testified in Sacramento this week in opposition, pushing back on misinformation and keeping the discussion grounded in real-world impact. We’re grateful for his time and advocacy.

The bill would restrict compounding of GLP-1 medications in ways we’ve seen attempted in other states this year, and this fight isn’t over. If you’re based in California or serve patients or prescribers there, there’s still time to make your voice heard before the April 21 hearing. Send a message to your Assembly member urging them to oppose AB 1990 – it takes just 30 seconds.

https://bit.ly/4tQQ90S

Kentucky

The Kentucky General Assembly adjourned its 2026 session this week and HB 729 died with it. The bill was aimed at unlicensed entities operating outside the regulated pharmacy system more than at legitimate compounding pharmacies. It applied broadly to all compounded drugs, not just GLP-1s, and would have introduced new permitting requirements, expanded inspection authority, and criminal penalties for certain compounding violations. APC is seeking a few amendments, and we’re hopeful we can find a way to support it when it returns next session.

04/17/2026

He’s here, there, and everywhere. Thanks to a grant from the Pharmacy Compounding Foundation, APC’s Scott Brunner was in Columbus last week to present at the Ohio Pharmacists Association’s annual conference. His topic? How GLP-1s Have Changed Compounding. This weekend, thanks to another of those grants, he’ll be in chilly Minot, North Dakota to present on A Pharmacy Compounding Public Policy Update. (Note to Scott: Pack a coat.)

FDA wants more teeth on drug advertising. In its budget request to Congress, the FDA is asking for new authority to declare drugs "misbranded" based on misleading direct-to-consumer advertising — including compounded drugs. The agency wants to be able to act against ads that overstate efficacy, imply broader FDA approval than exists, or fail to clearly disclose that a compounded product has not been reviewed for safety, effectiveness, or quality. The ask isn't surprising given the agency's recent marketing crackdown on telehealth platforms, but turning that enforcement posture into statutory authority would be a meaningful escalation.

Could compounders fill the insulin detemir void? A new citizen petition asks the FDA to declare insulin detemir — the drug formerly marketed by Novo Nordisk as Levemir before it was discontinued — a medically necessary drug in shortage and to permit outsourcing facilities to compound it. There's a legal wrinkle worth noting: compounding pharmacies are generally not permitted to compound biologics under federal law. But the FDA has exercised enforcement discretion on that front before, which makes this one worth keeping an eye on.

A skeptical take on the peptide push. This week, ProPublica published a deep dive into the FDA’s potential reversal on peptides. The piece centers on a core tension: RFK Jr. has called the 2023 decision to categorize 19 peptides as unsafe “illegal,” arguing the agency has no safety signal to justify the move. Three former FDA officials pushed back on the characterization, saying the decision was well-documented and supported by real safety concerns. While the article acknowledges a regulated compounding pathway would be meaningfully safer than the current gray market, it doesn’t fully embrace the argument either. It’s a useful snapshot of where the debate stands and a reminder that however this plays out, proponents will need to make a credible case on safety, not just access.

Read more at https://bit.ly/4vCgKjO

04/16/2026

Compliance is the topic, Philly is the town

APC's Scott Brunner and Tenille Davis will be speaking at Informa Connect's Compounding Pharmacy Compliance 2026 conference on June 9-10 — and with registration deadline savings on the table, now is a good time to lock in your spot. The event brings together compounding professionals, industry leaders, and regulators for two days of real talk on compliance challenges, quality standards, and where the industry is headed. APC members can register with a special code for 15% off — and if you register by April 17, you can save an additional $300. Contact info@a4pc.org to recieve your disount today.

04/15/2026

At a time when policy debates, drug shortages, and market shifts continue to redefine healthcare delivery, our new Snapshot of Pharmacy Compounding in America provides something essential: clear, industry-grounded insight from the compounding pharmacists and pharmacies doing the work every day.

Check out the Snapshot to learn more interesting facts about the work compounders are doing.

https://bit.ly/3OqlV5C

04/14/2026

California folks, this one’s urgent. California Assembly Bill 1990 would limit access to compounded GLP-1s and restrict prescriber decision-making—and hearings are happening now. If you are in California, take 30 seconds to speak up: https://bit.ly/4sC0n4d

04/14/2026

The best $20 you’ll spend this month

Effectively advocating for your compounding pharmacy and the patients you serve — the topic is too important to let cost be a barrier. On April 30, the founding leaders of Washington State's Compounding SIG, the group that helped defeat a serious legislative threat to compounding this year, are sharing exactly how they built their advocacy operation from the ground up. The CE credit is $20, and that's all we’re charging. The blueprint for protecting your pharmacy from the next legislative attack — that's the part that pays for itself many times over. If you caught last week's preview and have been on the fence, this is your nudge. Register now.

https://bit.ly/4vvbUF4

04/13/2026

State updates

California 🐻

Two bills are moved through the California legislature last week, and both are worth paying attention to.

AB 2141 cleared the Business & Professions Committee and would create a more streamlined process for the California Board of Pharmacy to resolve certain enforcement cases while maintaining full oversight — a practical fix that addresses a real gap in the current system. Chairman Marc Berman has also signed on as a principal co-author, a sign of growing support for the measure. APC has been advocating for exactly this kind of interim step, and we'll be watching its progress closely.

AB 1990, introduced by Representative Gibson, is a different story. Similar to legislation introduced in other states this year, it would significantly restrict compounding of GLP-1 drugs. The bill has hearings scheduled in the Business & Professions Committee on April 14 and the Privacy and Consumer Protection Committee on April 21. APC's Tenille Davis will be in Sacramento to testify in opposition at the first hearing.

Colorado 🐏

SB 26-066 has been laid over again. We'll keep you posted if anything changes with that bill.

On a separate front, APC Board Chair Philip Smyth testified last week in support of Colorado HB 1262, which aims to bring state law into alignment with the federal framework governing how 503A pharmacies and 503B outsourcing facilities work together. There's been persistent confusion at the state level about whether distribution from 503B facilities to 503A pharmacies constitutes wholesaling – despite FDA guidance making clear that it does not. HB 1262 clarifies that distinction without expanding compounding authority. An amendment was adopted during the hearing and the bill has advanced to the Committee of the Whole.

Georgia 🦌

The Georgia legislature officially adjourned its 2026 session on April 2 and HB 1361 died with it. The bill would have imposed significant new restrictions on pharmacy compounding, and like so many of its cousins introduced around the country this year, it didn't make it across the finish line. We'll be watching for what gets reintroduced when the next session begins.

04/13/2026

California Assembly Bill 1990 claims to target counterfeit drugs or bad actors, but in reality, it will deny patients access to the medications they need. For patients who depend on compounded treatments when commercial options aren’t available or appropriate, AB 1990 would mean fewer options and new barriers to care. That’s unacceptable.

Tell California lawmakers to stand with patients and protect pharmacy compounding:

What’s happeningLawmakers in California are considering a bill — Assembly Bill 1990 — that would restrict pharmacy compounding under the banner of safety and threaten the stability of California’s healthcare system.This bill claims to target...

04/10/2026

Welcome to our newest Diamond Corporate Patron!

CareValidate, an AI-powered digital health platform that helps pharmacies and healthcare organizations build and scale virtual care operations, has joined APC as our newest Diamond-level Corporate Patron.

“We’re thrilled to welcome CareValidate as a Diamond-level patron,” said APC CEO Scott Brunner. “Their support strengthens our ability to advocate for pharmacy compounders and the patients who depend on them.”

04/10/2026

PTCB's latest workforce data is out. Here's what matters for your pharmacy. The 2025 State of Pharmacy Technician Workforce report is out, and the big takeaway: the profession is maturing fast. More than 63% of technicians now view the role as a long-term career, up nearly 7.4% since 2022, and salary is following that commitment. Certified technicians earn roughly 20% more than their uncertified peers, a gap that's widening — and in compounding specifically, technicians average $23.46/hr, well above community pharmacy rates. The case for investing in your team's credentials and training has never been stronger.

https://bit.ly/4dECrcH

Pharmacy degrees: still worth every penny. Speaking of investing in your team, a new Washington Post op-ed highlights a study confirming what most pharmacists already know. A PharmD ranks second only to an MD in return on investment among graduate degrees, with graduates seeing a 68% cost-adjusted return on their education. That puts pharmacy well ahead of law, business, nursing, and just about everything else on the list.

https://wapo.st/4cGjog3

Peptide restrictions may be easing, but don’t hold your breath. The New York Times is reporting that the FDA is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides banned in 2023 over safety concerns. The push is coming from RFK Jr., who has been vocal about his use of peptides to heal injuries on multiple podcasts. Whether this is a flip-of-the-switch moment is still yet to be seen. The FDA is expected to put each peptide through the PCAC process before anything gets added back to the approved list. That takes time, which means in the interim, patients are likely getting research-grade or illicit products from overseas – exactly the problem a regulated pathway would solve.

https://nyti.ms/4cgnL13

04/08/2026

At a time when policy debates, drug shortages, and market shifts continue to redefine healthcare delivery, our new Snapshot of Pharmacy Compounding in America provides something essential: clear, industry-grounded insight from the compounding pharmacists and pharmacies doing the work every day.

Check out the Snapshot to learn more interesting facts about the work compounders are doing.

https://bit.ly/4c1fcbC

04/07/2026

APC's Scott Brunner, Tenille Davis, and Allie Jo Shipman will be speaking at upcoming state pharmacy association events this spring and summer — keep an eye out for their sessions if you're planning to go!

Ohio Pharmacists Association - April 9
Massachusetts Pharmacists Association - April 14
North Dakota Pharmacists Association - April 18
Utah Pharmacy Association - May 12
Arizona Pharmacy Association - June 5
Alabama Pharmacy Association - June 8
Maryland Pharmacists Association - June 26
Florida Pharmacy Association - July 17
Nevada Pharmacy Alliance - September 11